Spirocyclic compounds as tryptophan hydroxylase inhibitors
US11759462B2 · kind B2 · utility
0Cited by
10References
24Claims
0Family size
Assignee
Inventors
Key dates
| Filing date | Mar 15, 2021 |
| Grant date | Sep 19, 2023 |
| Priority date | — |
| Expiry date | May 15, 2041 |
Classification
- Technology area (CPC Y)Emerging Cross-Sectional Technologies
- CPC primaryY02A50/30
- WIPO fieldPharmaceuticals
- WIPO sectorChemistry
Abstract
The present invention is directed to spirocyclic compounds which are inhibitors of tryptophan hydroxylase (TPH), particularly isoform 1 (TPH1), that are useful in the treatment of diseases or disorders associated with peripheral serotonin including, for example, gastrointestinal, cardiovascular, pulmonary, inflammatory, metabolic, and low bone mass diseases, as well as serotonin syndrome, and cancer.
Source: USPTO / EPO open patent data. Objective bibliographic and citation counts.